Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › PEG-loxenatide

PEG-loxenatide

GLP-1 · s.c. weekly · Hansoh

Data cut 12 November 2026 · page built 16 November 2026 · 4 trial arms · 2 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
Hansoh (Fulaimei)
Mechanism
GLP-1
Route
s.c. weekly
Company
Hansoh
Highest development stage
approved
Status (as of data cut)
Approved in China for T2D (May 2019, Fulaimei) verify
Next milestone
—

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
T2D4 approved / in labelNMPA (China), May 2019 (Fulaimei)Hansoh announcement
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
PEX168 add-on to metformin phase 3b100 μg + metformint2d china24———−1.2————0.0 vs 0.0—press release
PEX168 add-on to metformin phase 3b200 μg + metformint2d china24———−1.1————0.0 vs 0.0—press release
PEX168 monotherapy phase 3a100 μgt2d china24361——−1.0 vs −0.21.6 vs 0.8—5.6 vs 0.02.4 vs 0.0——press release
PEX168 monotherapy phase 3a200 μgt2d china24361——−1.3 vs −0.22.5 vs 0.8—10.0 vs 0.08.3 vs 0.0——press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (12)
  • 100 μg · hba1c · publication
    The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
  • 100 μg · nausea · publication
    nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 100 μg · vomiting · publication
    vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 100 μg · ae_dc · publication
    (PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs
  • 200 μg · hba1c · publication
    The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
  • 200 μg · nausea · publication
    nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 200 μg · vomiting · publication
    vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 200 μg · ae_dc · publication
    (PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs
  • 100 μg + metformin · hba1c · publication
    in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
  • 100 μg + metformin · sae · Abstract, Results
    No treatment-emergent serious adverse events occurred.
  • 200 μg + metformin · hba1c · publication
    in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
  • 200 μg + metformin · sae · Abstract, Results
    No treatment-emergent serious adverse events occurred.

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT05172999
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
ObesityPhase 3completed2022-01 → 2025-1230Completed; results not in the atlas yetNCT05172999

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: PEG-loxenatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/peg-loxenatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.